Arovella Therapeutics (ASX:ALA) has entered into an exclusive option to license multiple patent families from Baylor College of Medicine to broaden the utility and enhance the performance of its iNKT cell platform.
Arovella options advances Baylor College of technology to enhance iNKT cell platform
May 5, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 6 November
November 6, 2026 - - Podcast -
Omico names laboratory partners to expand genomic profiling for Australians with cancer
November 6, 2026 - - Latest News -
Marie Guillet joins the European Australian Business Council board
November 6, 2026 - - Latest News -
The next agreements must end the culture of enforced silence
November 6, 2026 - - Latest News -
The lessons we can take from 'Robodebt' and the Reserve Bank reforms
November 6, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News

